Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized confirm trial

  1. Leo, A.D.
  2. Jerusalem, G.
  3. Petruzelka, L.
  4. Torres, R.
  5. Bondarenko, I.N.
  6. Khasanov, R.
  7. Verhoeven, D.
  8. Pedrini, J.L.
  9. Smirnova, I.
  10. Lichinitser, M.R.
  11. Pendergrass, K.
  12. Malorni, L.
  13. Garnett, S.
  14. Rukazenkov, Y.
  15. Martin, M.
Revue:
Journal of the National Cancer Institute

ISSN: 1460-2105,  0027-8874

Année de publication: 2014

Volumen: 106

Número: 1

Type: Article

DOI: 10.1093/JNCI/DJT337 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus